Navigation Links
Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time
Date:7/28/2011

class="discStyle" type="disc">
  • On a US GAAP basis, net cash provided by operating activities was $284 million (Q2 2010: $284 million).

    • Non GAAP net debt at June 30, 2011 was $972 million (December 31, 2010: $531 million), an increase of $441 million, as the net cash provided by operating activities in H1 2011 and existing cash resources were used to fund the acquisition of Advanced BioHealing Inc. ("ABH"), other capital expenditure, the dividend payment and the purchase of shares by the Employee Share Ownership Trust ("ESOT").

    2011 OUTLOOK


    The strong first half performance has further underpinned our confidence in meeting increased market consensus for 2011 earnings. This includes absorbing the marginal dilution of the acquisition of ABH.

    For the full year we expect to see strong product sales growth, and royalty and other revenues combined to be down 10% compared to 2010. Taken together, year on year growth of total revenues in the second half is expected to be marginally lower than the rate of 22% seen in the first half.

    Gross margins are expected to be marginally diluted in the second half as a result of the inclusion of ABH, although gross margins for the full year should still be in line with those recorded in 2010.

    As we have previously indicated, we have identified significant opportunities for future growth by advancing our pipeline and continuing the international expansion of our portfolio. Combined R&D and SG&A, which was set to increase by 13% is now expected to increase in the full year by around 20% year on year. This reflects the inclusion of ABH's cost base (representing an increase in our 2011 full year cost guidance of 5%) and our view of the likely impact of foreign exchange movements on our R&D and SG&A plans in 2011.

    We continue to expect our Non GAAP effective tax rate to be between 22 and 24%.

    Overall, the o
    '/>"/>

    SOURCE Shire plc
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

    Related biology technology :

    1. Neogen Reports 27% Increase in Quarterly Net Income
    2. Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be
    3. Microbix Has Best-Ever Quarterly Sales
    4. Amylin Pharmaceuticals Announces Third Quarter Product Revenues; Quarterly Update Conference Call Canceled
    5. China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010
    6. Shires Replenished Portfolio Drives Excellent Quarterly Performance
    7. Quest Diagnostics Declares Quarterly Cash Dividend
    8. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
    9. Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
    10. Abbott Declares 343rd Consecutive Quarterly Dividend
    11. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/19/2014)... (PRWEB) October 19, 2014 The Asian ... in Asian with analysis and forecast of revenue. The ... grow to around $463.9 million by 2018, at a ... Browse through the TOC of the Asian Automatic patient ... analysis provided. This also provides a glimpse of the ...
    (Date:10/19/2014)... The Asian Orthopedic braces and support systems report ... and forecast of revenue. The Orthopedic braces and support systems ... million by 2018, at a developing CAGR of 4.4% from ... Asian Orthopedic braces and support systems market, to get an ... glimpse of the segmentation of orthopedic braces and support systems ...
    (Date:10/18/2014)... 2014 The “Human Insulin Market- ... Acting, Premixed), Modern Human Insulin (Rapid Acting, Long ... Novomix, Tresiba, Others) - Forecast to 2018” provides ... challenges, opportunities, current market trends, and strategies impacting ... estimates and forecasts of the revenue and share ...
    (Date:10/18/2014)... The Asian arthroscopic devices report defines ... and forecast of revenue. The arthroscopic devices market in ... 2018, at a CAGR of 6.5% from 2013 to ... arthroscopic devices market, to get an idea of the ... the segmentation of arthroscopic devices market in the same ...
    Breaking Biology Technology:The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 2The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 3The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 4
    ... - - ... -, SOUTH SAN FRANCISCO, Calif., Aug. 17 ... U.S. Food and Drug,Administration (FDA) has approved Zingo(TM) (lidocaine ... analgesia to reduce the pain associated with venous access,procedures, ...
    ... (Nasdaq: IDEV ) today announced that it ... and Drug Administration (FDA) for,VALSTAR(R). VALSTAR, a sterile ... product approved by the FDA for therapy of,bacillus ... bladder. VALSTAR was removed from the market ...
    ... Union announced today they,have entered into a five-year ... in Region 3 to provide RealTime1(TM) (RT1(TM)),software at ... and the,US Virgin Islands. The Region 3 Genetics ... funding for another five-year period.,With this renewal, Region ...
    Cached Biology Technology:Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 2Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 3Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 4Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 5Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 2Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 3Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 4Digital Union's RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative 2
    (Date:10/18/2014)... for evaluation of suspected genetic conditions, whole-exome sequencing ... including detection of a number of rare genetic ... to a study appearing in JAMA . ... the American Society of Human Genetics annual meeting. ... regions of thousands of genes simultaneously using next-generation ...
    (Date:10/17/2014)... news release is available in German . ... millions of sperms every day in order to reproduce? And ... are the topic of the latest issue of the research ... 2014). The evolutionary biologist Steven Ramm from Bielefeld University Bielefeld ... it is not unusual for a female to copulate with ...
    (Date:10/16/2014)... constantly wages war on the human body. Battles ... stalemate. In pancreatic cancer, this stalemate—known as tumor ... aggressively malignant, a phenomena that is poorly understood. ... the laboratory of Salvatore Torquato, a Professor of ... conditions surrounding tumor dormancy and the switch to ...
    Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2Modeling tumor dormancy 2
    ... genes can reveal not only the "lifestyle" of marine microbes ... finding means researchers may be able to predict the types ... the genomes of just a few dominant species, according to ... Wales. As well, it may reveal new insights into the ...
    ... removed during liposuction conceal versatile cells that are more ... cells, or iPS cells, than are the skin cells ... study from Stanford,s School of Medicine. "We,ve identified a ... of the research, Michael Longaker, MD, who has called ...
    ... for 50 percent of the fish consumed globally, according to ... while the industry is more efficient than ever, it is ... large amounts of feed made from wild fish harvested from ... the Sept. 7 online edition of the Proceedings of ...
    Cached Biology News:Genomes reveal bacterial lifestyles: Research 2'Liposuction leftovers' easily converted to IPS cells, Stanford study shows 2'Liposuction leftovers' easily converted to IPS cells, Stanford study shows 3Half of the fish consumed globally is now raised on farms, study finds 2Half of the fish consumed globally is now raised on farms, study finds 3
    ... experiment based analysis package designed with easy ... and powerful functionality., Image acquisition interface is ... easy image capture. Sequential and dynamic ... Saturation Warning Single ...
    ...
    ANTI DIPHTH TOX A SU...
    ... Taq DNA Polymerase is a thermostable recombinant ... in primer extension and other molecular biology ... which provides easy and quick identification of ... allows confirmation of complete mixing. The inert ...
    Biology Products: